Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

Kyung Jin Eoh, Hyung Seok Park, Ji Soo Park, Seung Tae Lee, Jung Woo Han, Jung Yun Lee, Sunghoon Kim, Sang Wun Kim, YoungTae Kim, Eun Ji Nam

Research output: Contribution to journalArticle

Abstract

Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

Original languageEnglish
Pages (from-to)6947-6953
Number of pages7
JournalAnticancer research
Volume38
Issue number12
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Exons
Mutation
Disease-Free Survival
Survival
Ovarian epithelial cancer
Recurrence

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Eoh, K. J., Park, H. S., Park, J. S., Lee, S. T., Han, J. W., Lee, J. Y., ... Nam, E. J. (2018). Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons. Anticancer research, 38(12), 6947-6953. https://doi.org/10.21873/anticanres.13073
Eoh, Kyung Jin ; Park, Hyung Seok ; Park, Ji Soo ; Lee, Seung Tae ; Han, Jung Woo ; Lee, Jung Yun ; Kim, Sunghoon ; Kim, Sang Wun ; Kim, YoungTae ; Nam, Eun Ji. / Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons. In: Anticancer research. 2018 ; Vol. 38, No. 12. pp. 6947-6953.
@article{b73e9b8a4b954a7f82d7ef2f886b3205,
title = "Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons",
abstract = "Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0{\%}) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.",
author = "Eoh, {Kyung Jin} and Park, {Hyung Seok} and Park, {Ji Soo} and Lee, {Seung Tae} and Han, {Jung Woo} and Lee, {Jung Yun} and Sunghoon Kim and Kim, {Sang Wun} and YoungTae Kim and Nam, {Eun Ji}",
year = "2018",
month = "12",
day = "1",
doi = "10.21873/anticanres.13073",
language = "English",
volume = "38",
pages = "6947--6953",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "12",

}

Eoh, KJ, Park, HS, Park, JS, Lee, ST, Han, JW, Lee, JY, Kim, S, Kim, SW, Kim, Y & Nam, EJ 2018, 'Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons', Anticancer research, vol. 38, no. 12, pp. 6947-6953. https://doi.org/10.21873/anticanres.13073

Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons. / Eoh, Kyung Jin; Park, Hyung Seok; Park, Ji Soo; Lee, Seung Tae; Han, Jung Woo; Lee, Jung Yun; Kim, Sunghoon; Kim, Sang Wun; Kim, YoungTae; Nam, Eun Ji.

In: Anticancer research, Vol. 38, No. 12, 01.12.2018, p. 6947-6953.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Distinct clinical courses of epithelial ovarian cancer with mutations in BRCA1 5’ and 3’ exons

AU - Eoh, Kyung Jin

AU - Park, Hyung Seok

AU - Park, Ji Soo

AU - Lee, Seung Tae

AU - Han, Jung Woo

AU - Lee, Jung Yun

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, YoungTae

AU - Nam, Eun Ji

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

AB - Background/Aim: This study aimed to determine the effect of different BRCA1 exonal mutations on the clinical course of epithelial ovarian cancer (EOC). Patients and Methods: Clinicopathological variables and survival outcomes were compared among 53 primary EOC patients with pathogenic BRCA1 mutations in exons 1-11 (5’ mutations) and in exons 12-24 (3’ mutations). Results: BRCA1 5’ exonal mutations were found in 35 (66.0%) patients. The median follow-up period was 40 months. Clinicopathological variables remained unchanged between the two groups. Patients with 5’mutations had a significantly longer progression-free survival than those with C-terminal mutations (p=0.034), better predicting progression-free survival [2.923 (1.402-6.093), p=0.004], but not overall survival in cases of multiple relapses (p=0.497). Conclusion: N-terminal BRCA1 mutations in EOC patients are associated with favourable primary progression-free survival, a trend observed only in primary progression-free survival, not in overall survival.

UR - http://www.scopus.com/inward/record.url?scp=85057538459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057538459&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13073

DO - 10.21873/anticanres.13073

M3 - Article

VL - 38

SP - 6947

EP - 6953

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 12

ER -